{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:24:26Z","timestamp":1784899466566,"version":"3.55.0"},"reference-count":20,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2020]]},"DOI":"10.1620\/tjem.251.87","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T22:06:20Z","timestamp":1591913180000},"page":"87-90","source":"Crossref","is-referenced-by-count":76,"title":["Uric Acid Elevation by Favipiravir, an Antiviral Drug"],"prefix":"10.1620","volume":"251","author":[{"given":"Eikan","family":"Mishima","sequence":"first","affiliation":[{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Anzai","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Chiba University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Abe","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine"},{"name":"Division of Medical Science, Tohoku University Graduate School of Biomedical Engineering"},{"name":"Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","unstructured":"Ben Salem, C., Slim, R., Fathallah, N. &amp; Hmouda, H. (2017)  Drug-induced hyperuricaemia and gout.  <i>Rheumatology <\/i>(<i>Oxford<\/i>), 56, 679-688."},{"key":"2","doi-asserted-by":"crossref","unstructured":"Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J. &amp; Wang, X. (2020)  Favipiravir versus arbidol for COVID-19: a randomized clinical trial.  <i>medRxiv<\/i>, doi:10.1101\/2020.03.17.20037432.","DOI":"10.1101\/2020.03.17.20037432"},{"key":"3","doi-asserted-by":"publisher","unstructured":"Du, Y.X. &amp; Chen, X.P. (2020)  Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection.  <i>Clin. Pharmacol. Ther.<\/i>, doi: 10.1002\/cpt.1844. [Epub ahead of print].","DOI":"10.1002\/cpt.1844"},{"key":"4","unstructured":"Fujifilm Toyama Chemical Co., Ltd. (Fujifilm) (2019)  The drug interview form of favipiravir (Avigan<sup>\u00ae<\/sup>) (April. 2019 version). http:\/\/fftc.fujifilm.co.jp\/med\/abigan\/pack\/pdf\/abigan_if_01.pdf [<i>Accessed<\/i>: May 5, 2015] (in Japanese)."},{"key":"5","unstructured":"Fujita Health University Hospital (2020)  Interim report of observational study of favipiravir (May. 26. 2020 version). http:\/\/www.kansensho.or.jp\/uploads\/files\/topics\/2019ncov\/covid19_favip_0526.pdf [<i>Accessed<\/i>: May 27, 2015] (in Japanese)."},{"key":"6","unstructured":"Furuta, Y., Komeno, T. &amp; Nakamura, T. (2017)  Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.  <i>Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.<\/i>, 93, 449-463."},{"key":"7","unstructured":"Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H. &amp; Shiraki, K. (2002)  In vitro and in vivo activities of anti-influenza virus compound T-705.  <i>Antimicrob. Agents Chemother.<\/i>, 46, 977-981."},{"key":"8","unstructured":"Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H. &amp; Shiraki, K. (2005)  Mechanism of action of T-705 against influenza virus.  <i>Antimicrob. Agents Chemother.<\/i>, 49, 981-986."},{"key":"9","doi-asserted-by":"crossref","unstructured":"Hirano, M. &amp; Peters, G.J. (2016)  Advances in purine and pyrimidine metabolism in health and diseases.  <i>Nucleosides Nucleotides Nucleic Acids<\/i>, 35, 495-501.","DOI":"10.1080\/15257770.2016.1218022"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Jutabha, P., Anzai, N., Wempe, M.F., Wakui, S., Endou, H. &amp; Sakurai, H. (2011)  Apical voltage-driven urate efflux transporter NPT4 in renal proximal tubule.  <i>Nucleosides Nucleotides Nucleic Acids<\/i>, 30, 1302-1311.","DOI":"10.1080\/15257770.2011.616564"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Li, F., Guo, H., Zou, J., Chen, W., Lu, Y., Zhang, X., Fu, C., Xiao, J. &amp; Ye, Z. (2018)  Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study.  <i>BMC Nephrol.<\/i>, 19, 95.","DOI":"10.1186\/s12882-018-0892-7"},{"key":"12","unstructured":"Louthrenoo, W., Hongsongkiat, S., Kasitanon, N., Wangkaew, S. &amp; Jatuworapruk, K. (2015)  Effect of antituberculous drugs on serum uric acid and urine uric acid excretion.  <i>J. Clin. Rheumatol.<\/i>, 21, 346-348."},{"key":"13","doi-asserted-by":"crossref","unstructured":"Madelain, V., Nguyen, T.H., Olivo, A., de Lamballerie, X., Guedj, J., Taburet, A.M. &amp; Mentre, F. (2016)  Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials.  <i>Clin. Pharmacokinet.<\/i>, 55, 907-923.","DOI":"10.1007\/s40262-015-0364-1"},{"key":"14","unstructured":"Ministry of Health, Labour and Welfare (MHLW) (2016)  Company data about Avigan<sup>\u00ae<\/sup> in Pandemic Influenza Subcommittee on November, 25, 2016. https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000143922.pdf [<i>Accessed<\/i>: May 5, 2015] (in Japanese)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"Misawa, K., Hasegawa, T., Mishima, E., Jutabha, P., Ouchi, M., Kojima, K., Kawai, Y., Matsuo, M., Anzai, N. &amp; Nagasaki, M. (2020)  Contribution of rare variants of the SLC22A12 gene to the missing heritability of serum urate levels.  <i>Genetics<\/i>, 214, 1079-1090.","DOI":"10.1534\/genetics.119.303006"},{"key":"16","doi-asserted-by":"publisher","unstructured":"Mishima, E., Mori, T., Nakajima, Y., Toyohara, T., Kikuchi, K., Oikawa, Y., Matsuhashi, T., Maeda, Y., Suzuki, T., Kudo, M., Ito, S., Sohara, E., Uchida, S. &amp; Abe, T. (2020)  HPRT-related hyperuricemia with a novel p.V35M mutation in HPRT1 presenting familial juvenile gout.  <i>CEN Case Rep.<\/i>, doi: 10.1007\/s13730-020-00459-9. [Epub ahead of print].","DOI":"10.1007\/s13730-020-00459-9"},{"key":"17","unstructured":"Naesens, L., Guddat, L.W., Keough, D.T., van Kuilenburg, A.B., Meijer, J., Vande Voorde, J. &amp; Balzarini, J. (2013)  Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir).  <i>Mol. Pharmacol.<\/i>, 84, 615-629."},{"key":"18","unstructured":"Obach, R.S., Huynh, P., Allen, M.C. &amp; Beedham, C. (2004)  Human liver aldehyde oxidase: inhibition by 239 drugs.  <i>J. Clin. Pharmacol.<\/i>, 44, 7-19."},{"key":"19","unstructured":"Otani, N., Ouchi, M., Hayashi, K., Jutabha, P. &amp; Anzai, N. (2017)  Roles of organic anion transporters (OATs) in renal proximal tubules and their localization.  <i>Anat. Sci. Int.<\/i>, 92, 200-206."},{"key":"20","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) (2014)  Report on the deliberation results: avigan. Japan; Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau. http:\/\/www.pmda.go.jp\/files\/000210319.pdf [<i>Accessed<\/i>: May 5, 2020]."}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/251\/2\/251_87\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T03:44:20Z","timestamp":1592019860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/251\/2\/251_87\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.251.87","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}